Meet Eloralintide:
Weight Loss, Side Effects and the Tirzepatide Question

Eloralintide, formerly LY3841136, is an investigational once-weekly selective amylin-receptor agonist from Eli Lilly. It targets a satiety pathway distinct from the GLP-1 and GIP receptors activated by drugs such as semaglutide and tirzepatide.

In a randomized 48-week Phase 2 trial, the highest fixed dose produced 20.1% mean weight loss under the efficacy estimand, compared with 0.4% for placebo. That is a serious clinical signal. It is not an approval, a head-to-head victory over an incretin or evidence for a do-it-yourself dosing plan.

Amylin is secreted alongside insulin after eating. Its signaling contributes to satiety, slows gastric emptying and suppresses post-meal glucagon. Eloralintide is a long-acting amylin analogue modified with a C20 fatty diacid to support albumin binding and once-weekly exposure.

The design emphasizes amylin-1 receptor selectivity. Lilly's discovery work reported roughly 12-fold greater activity at human AMY1R than at the calcitonin receptor. In diet-induced obese rats, treatment reduced food intake and body weight predominantly through fat-mass loss. Those findings explain the development strategy; they do not prove a human body-composition advantage over less selective amylin drugs.

A single-ascending-dose study in healthy participants reported mean week-four weight changes of −2.5% after 4 mg and −4.4% after 12 mg, versus +0.6% with placebo. A later 12-week multiple-dose study in adults with obesity or overweight found dose-group reductions ranging from 2.6% to 11.3% without dose escalation.

Those studies supported weekly dosing and justified a larger trial. Their small cohorts and short follow-up were not enough to establish long-term efficacy or a preferred clinical dose.

The Phase 2 trial randomized 263 adults at 46 U.S. research centers. Participants had obesity, or overweight with at least one weight-related comorbidity, and did not have type 2 diabetes. Mean baseline weight was 109.1 kg and mean BMI was 39.1 kg/m²; 78% of participants were women.

The primary endpoint was percentage change in body weight after 48 weeks. The results below use the efficacy estimand, which estimates the effect if participants remained on their assigned treatment. The reported comparisons were not adjusted for multiplicity.

The weight-loss curves had not clearly plateaued at week 48. Comparisons with tirzepatide or semaglutide remain cross-trial comparisons: the populations, durations and analysis plans differ, and no head-to-head eloralintide trial has answered which treatment is superior.

The lower doses were relatively quiet: nausea occurred in 11% of the 1 mg group and 13% of the 3 mg group, compared with 14% on placebo. At 6 mg, nausea reached 64%; it was 33% at 9 mg, 54% in the 6-to-9 mg escalation arm and 25% with the slower 3-to-6-to-9 mg escalation.

Fatigue also increased in the higher-dose arms, reaching 43% at 9 mg and 46% in the 6-to-9 mg arm, versus 12% with placebo. These results do not support the broad claim that receptor selectivity makes gastrointestinal effects negligible. They suggest that dose and escalation strategy matter.

The rationale is straightforward: amylin and incretin drugs act through different receptors while overlapping on appetite and gastric-emptying effects. Combining them could deepen weight loss, improve treatment options after an incretin plateau or increase adverse effects—or some mixture of all three.

A completed Phase 1 study evaluated eloralintide alone and with tirzepatide primarily for pharmacokinetics, safety and tolerability. A separate Phase 2 combination study in adults with type 2 diabetes completed in 2026, but no peer-reviewed efficacy paper was available when this draft was reviewed. Lilly has said combination data are expected in the second half of 2026.

The clearest published combination result remains preclinical: an ADA 2026 abstract reported that eloralintide plus tirzepatide reduced food intake, body weight and fat mass more than either treatment alone in diet-induced obese rats. Rat synergy is a reason to test the pairing in people, not evidence of a human percentage or a safe schedule.

Lilly moved eloralintide into a broad Phase 3 program after the monotherapy result. ENLIGHTEN-1 is studying adults with obesity or overweight without type 2 diabetes. ENLIGHTEN-2 covers participants with type 2 diabetes, with additional studies in obstructive sleep apnea and knee osteoarthritis.

ENLIGHTEN-6 is especially relevant to the combination question. It is testing eloralintide versus placebo in people with persistent obesity or overweight who are already receiving a stable weekly incretin. That design asks whether amylin therapy can add value after background incretin treatment rather than assuming both drugs should be maximized together.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates GIP and GLP-1 receptors. Eloralintide acts through amylin receptors, including brainstem circuits involved in satiation. The pathways converge on eating behavior but are not interchangeable.

Cagrilintide is another long-acting amylin analogue, while CagriSema combines it with semaglutide. Differences in receptor selectivity are scientifically interesting, but they do not establish clinical superiority. Only direct trials can answer whether selectivity meaningfully changes efficacy, tolerability or lean-mass preservation.

Eloralintide is the first selective amylin agonist with a published 48-week result in the same broad efficacy conversation as leading incretin therapies. That makes it one of the most consequential obesity-drug candidates now in development.

The caveats are equally important. High-dose tolerability was not placebo-like, direct comparisons with existing drugs do not exist and the most compelling tirzepatide-combination claims are still ahead of the peer-reviewed evidence. Phase 3 will determine whether the Phase 2 signal holds at scale and where an amylin add-on belongs in actual care.